7/6/2020  7:47:19 PM Chg. +0.22 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
8.26USD +2.67% 1,782
Turnover: 14,323.45
-Bid Size: - -Ask Size: - 277.27 mill.USD 0.00% -

Business description

AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women's health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.
 

Management board & Supervisory board

CEO
Scott Myers
Management board
Edward Myles, Joseph D. Vittiglio, Julie Krop, Kelly Schick, Tony Casciano
Supervisory board
Gino Santini, Anne M. Phillips, Barbara Deptula, Davey S. Scoon, David Johnson, James R. Sulat, John A. Fallon, Kathrine O’Brien, Paul Fonteyne, Robert J. Perez, Scott Myers
 

Company data

Name: AMAG Pharmaceuticals Inc.
Address: 1100 Winter Street,Waltham, Massachusetts 02451, USA
Phone: +1-617-498-3300
Fax: -
E-mail: contactus@amagpharma.com
Internet: www.amagpharma.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 11.16%
IPO date: -

Investor relations

Name: Linda Lennox
IR phone: +1-617-498-2846
IR Fax: -
IR e-mail: llennox@amagpharma.com

Main Shareholders

BlackRock, Inc.
 
16.26%
Camber Capital Management LLC
 
12.81%
Armistice Capital, LLC
 
12.55%
Freefloat
 
11.16%
Caligan Partners
 
10.25%
Palo Alto Investors, LLC
 
8.89%
The Vanguard Group
 
8.25%
State Street Corporation
 
7.92%
Goldman Sachs
 
5.99%
Others
 
5.92%